William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care
William Pao, Adjunct Professor of Pharmacology and Medicine at Joan and Sanford I. Weill Medical College of Cornell University, Chief Executive Officer at Revelio Therapeutics, shared a post on LinkedIn about a recent article by him, published in PNAS, adding:
“Please join me in wishing congratulations to Kunihiro Hattori, Takehisa Kitazawa and Tomoyuki Igawa from Chugai Pharmaceutical Co., Ltd.!
They have just been awarded by The Albert and Mary Lasker Foundation the 2026 Lasker-Debakey Clinical Medical Research Award for invention of a bispecific antibody that joins blood clotting Factors IXa (FIXa) and X (FX), restoring deficient Factor VIII (FVIII) activity in patients with hemophilia A and preventing severe bleeding in this hereditary disorder.
Over the span of 10 years, starting in 2000, Hattori – a molecular and hematology biologist, Kitazawa – a hematology biologist and translational researcher, and Igawa – a biochemist and protein engineer, conceived, designed and created emicizumab, a novel FVIII-mimetic.
Their collective research efforts demonstrate how imagination, determination and multidisciplinary scientific research come together to improve patients’ lives.
Their journey highlights what it takes to make true first-in-class breakthrough medicines for patients.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day
-
Oct 17, 2026, 23:18Maha Othman: Establishing ISTH-BAT Reference Ranges for Children and Adolescents
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland